Silence Therapeutics applies The QCA Corporate Governance Code. Details of our Corporate Governance arrangements can be found below.
Policy and strategy
The Board of Directors is responsible for approving the Company’s policy and strategy. It meets on a regular basis and has a schedule of matters specifically reserved for it to consider. The executive management team supply the Board with appropriate and timely information and the Directors are free to seek any further information they consider necessary. All Directors have access to regular training and independent professional advice at the Company’s expense.
The Board is responsible for maintaining a strong system of internal controls to safeguard shareholders’ investment and the Company’s assets and for reviewing its effectiveness. The system of internal financial control is designed to provide reasonable, but not absolute, assurance against material misstatement or loss.
An Audit & Risk committee has been established and comprises three Non-Executive directors. The Committee is responsible for ensuring that the financial performance of the Group is properly monitored and reported on, as well as meeting the Company’s auditor and reviewing any reports from the auditor regarding accounts and internal control systems.
Corporate governance principles
On 19 July 2018, the Board approved the application of The QCA Corporate Governance Code (2018 edition) (the Code). The Board views this an appropriate corporate governance framework for Silence Therapeutics plc, and consideration has been given to each of the ten principles set out in the Code. Click here to view the application of each principle. Compliance with the Code was last reviewed on 14 April 2020.
The Remuneration Committee assists the board in the discharging of its responsibilities related to remuneration of the Company’s executive officers.
Members: James Ede-Golightly, Alistair Gray, Dave Lemus
Audit & Risk Committee
The Audit & Risk Committee assists the board’s oversight of accounting and financial reporting processes and the audits of the Company’s financial statements.
Members: Alistair Gray, James Ede-Golightly, Dave Lemus
The Nominations Committee recommends to the board those persons to be nominated for election as directors at any shareholders meeting.
Members: Iain Ross, James Ede-Golightly, Alistair Gray, Dave Lemus
Relations with shareholders
Silence Therapeutics values the views of its shareholders and recognises their interest in the Company’s strategy and performance. The Annual General Meeting, Annual Report, interim announcements and company website are all used to communicate with private investors and they are encouraged to participate.